Triple Negative Breast Cancer Clinical Trials
Triple negative breast cancer clinical trials offer access to the latest treatment options before they become commercially available. Clinical studies can include already approved therapies combined with of other innovative treatments.
Triple negative breast cancer clinical trials aim to discover new treatment approaches that can be combined with FDA-approved drugs and methods or given on their own. Through these studies, promising targeted therapies are being explored that could benefit participants and help treat breast cancer.
Triple Negative Breast Cancer Clinical Trials Information
Cancer clinical trials are crucial in finding and proving new ways to fight cancer. Through these studies, healthcare professionals explore opportunities to improve patients’ quality of life and/or their chance of survival. All the drugs that have already been approved for treatments, must have gone through the rigorous clinical trial process before approval.
A triple negative breast cancer (TNBC) diagnosis means that the 3 most common types of receptors, (estrogen, progesterone, and the HER-2/neu gene), that feed many breast cancers, are not present in the tumor. In other words, the breast cancer cells tested negative for epidermal growth factor receptor 2, estrogen receptors, and progesterone receptors.
Known treatments, such as hormone therapy and drugs targeting estrogen, progesterone and HER-2, may not be effective because cancer-causing tumor cells do not contain the necessary receptors. Using chemotherapy to treat triple negative breast cancer is still an effective treatment option. In fact, triple negative breast cancer may respond better to chemotherapy in the early stages than many other types of cancer. In addition, clinical trials are conducted to find out how different treatments are performing in triple negative breast cancer treatment. By participating in a clinical trial, you can have a major impact on this important research and medical progress for you and future patients who could benefit from the treatment.
How is TNBC Diagnosed?
After breast cancer is diagnosed using imaging tests and biopsies, the cancer cells are examined for specific features. If the cancer cells do not have estrogen or progesterone receptors and do not produce enough of the HER2 protein, it is considered triple negative breast cancer.
Treatment of Triple Negative Breast Cancer
Triple negative breast cancer has fewer treatment options than other types of breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors, hormone therapy, or enough HER2 protein for drugs targeting those receptors to work.
If the cancer has not spread to different areas of the body, surgery is an option for treatment in the early stages. In order to shrink a large tumor, the patient can be treated with chemotherapy until they are eligible for surgery.
Risk Factors for Breast Cancer
There are many risk factors that may contribute to a breast cancer diagnosis. These could be genes inherited from family, aging, dietary habits, lifestyle or other causes. Having one or more of these risk factors does not mean that you will ever be diagnosed with breast cancer. Regular screenings and self-check exams will assist in minimizing the risks.